Constitutive phosphorylation of Janus kinase 2 in the GL15 glioblastoma derived human cell line

Miriam Sciaccaluga1, Gian Luigi Gianfranceschi, Simone Rocco

  • 1Department of Cellular and Environmental Biology, Section of Cellular and Molecular Biology, University of Perugia, via Pascoli, 06100 Perugia, Italy.

Oncology Reports
|December 5, 2006
PubMed

Insights

This study identifies Janus kinase 2 (JAK2) as constitutively active in glioblastoma cells, suggesting it as a potential therapeutic target. Inhibiting JAK2 with tyrphostin AG490 halts glioma cell cycle progression.

Area of Science:

  • Neuro-oncology
  • Molecular Biology
  • Cell Biology

Background:

  • Gliomas may arise from mutated glial precursor cells.
  • Modulating developmental CNS pathways could impact glioma behavior.
  • GL15 glioblastoma cells express nestin and vimentin, characteristic of astrocyte precursors.

Purpose of the Study:

  • Investigate molecular mechanisms in glioblastoma cells.
  • Determine the role of Janus kinase 2 (JAK2) in GL15 cells.
  • Evaluate the effect of JAK2 inhibition on glioma cell proliferation.

Main Methods:

  • Analyzed nestin and vimentin expression in GL15 cells.
  • Assessed JAK2 phosphorylation status in GL15 cells.
  • Treated GL15 cells with tyrphostin AG490 and analyzed cell cycle progression.

Main Results:

  • GL15 cells exhibit characteristics of astrocyte restricted precursors.
  • GL15 cells display constitutively phosphorylated JAK2, not due to chromosomal aberrations.
  • Tyrphostin AG490 induced S phase arrest and G2 phase impairment in GL15 cells.

Conclusions:

  • Abnormally activated JAK2 in glioblastoma cells presents a potential therapeutic target.
  • JAK2 inhibition offers a selective pharmacological approach for specific glioblastomas.
  • Targeting JAK2 may be effective in glioblastomas with precursor cell features and genetic alterations.

Related Concept Videos

PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a rapamycin-insensitive companion...
The JAK-STAT Signaling Pathway01:20

The JAK-STAT Signaling Pathway

Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as  SH2...
cAMP-dependent Protein Kinase Pathways01:25

cAMP-dependent Protein Kinase Pathways

Cyclic Adenosine Monophosphate (cAMP) is an essential second messenger that activates protein kinase A (PKA) and regulates various biological processes. A single epinephrine molecule binds to GPCR and activates several heterotrimeric G proteins, each stimulating multiple adenylyl cyclase, amplifying the signal, and synthesizing large numbers of cAMP molecules. Small changes in cAMP concentration affect PKA activity. The binding of four cAMP molecules induces a conformational change in PKA,...
The Ras Gene02:38

The Ras Gene

The Ras-gene-encoded proteins are regulators of signaling pathways controlling cell proliferation, differentiation, or cell survival. The Ras-gene family in humans constitutes three primary members—the HRas, NRas, and KRas. These genes code for four functionally distinct yet closely related proteins—the HRas, NRas, KRas4A, and KRas4B. The involvement of mutant Ras genes in human cancer was first discovered in 1982 and is among the most common causes of human tumorigenesis.
Ras is a superfamily...
Small GTPases - Ras and Rho01:24

Small GTPases - Ras and Rho

Ras and Rho are small monomeric GTPases that act downstream of receptor tyrosine kinase (RTK) and regulate various cellular processes. These GTPases switch between active and inactive states by binding to guanine nucleotides.
Three regulatory proteins control their activity:
Amplifying Signals via Enzymatic Cascade01:22

Amplifying Signals via Enzymatic Cascade

When a ligand binds to a cell-surface receptor, the receptor's intracellular domain changes shape, which may either activate its enzyme function or allow its binding to other molecules. The initial signal is amplified by most signal transduction pathways. This means that a single ligand molecule can activate multiple molecules of a downstream target. Proteins that relay a signal are most commonly phosphorylated at one or more sites, activating or inactivating the protein. Kinases catalyze the...